Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzalkonium chloride is a quaternary ammonium compound used as an antiseptic and surfactant. In the context of clinical research at Georgetown University, it is the active antimicrobial component in BlastX Antimicrobial Wound Gel and TorrentX Antimicrobial Wound Wash. These products utilize Next Science's proprietary Xbio technology, which is designed to deconstruct the protective extracellular polymeric substance (EPS) matrix of bacterial biofilms. By disrupting this matrix, benzalkonium chloride can effectively penetrate and eliminate bacteria that are otherwise protected from standard treatments. This dual action aims to reduce bacterial burden and accelerate the healing of chronic lower extremity wounds, such as diabetic foot ulcers and venous leg ulcers, where biofilm presence often stalls recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzalkonium chloride (Next Science).